Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2004)	12/21/2007 1:05:51 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

NRMX Had a good intraday spike at 12:19 pm ET on an uptick of 14Ks & was up 19.27% at the time.(It is up only 10% at present.<g>) bigcharts.marketwatch.com On Tuesday the Motley Fool said that the refusal of the EMEA to approve KIACTA, was the "Final Nail in Neurochem's Coffin".<g> NRMX reported a lower loss in the 3rdQ in spite of 57% lower revenues, but the ELs for 2007 & 2008 are around $1.85 & $1.20/shr, & it has around $1.90 negative CF The stock is down from its Dec 2006 H of $26.51. It reportedly has around $71M in cash, but it doesn't have any other drug candidates which could be submitted for approval to the FDA or the EMEA.(Besides its KIACTA for amyloidosis,the other drug in its pipeline is tramiprosate, which it plans to market as ALZHEMED for Alzheimer's & CEREBRIL for cvas due to cerebral amyloid angiopathy. bigcharts.marketwatch.com Bernard